Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Hong Kong developers raise prices of flats by up to 70 per cent as record Kai Tak land sale boosts confidence

2018-05-22 scmp
Analysts say the surge has been fuelled by a land auction at the site of the city’s former airport which fetched HK$25.16 billion, a record price for a residential plot
SUHJY 0016 SHGKF SHGKY KRYPY 0086 KRYPF 0683 SUHJF

0
Sun Hung Kai pays HK$25.1 billion for Hong Kong’s costliest residential land at Kai Tak

2018-05-15 scmp
One of the city’s largest land owners won the 14th government tender by paying a record HK$25.1 billion for a plot with gross floor area of 1.42 million sq ft
SHGKY KRYPY 0086 LFSYF 0083 1212 0683 0012 SUHJF SUHJY 0016 SHGKF 0813 M35 SHMAY SIOPF KRYPF LFSYY

0
Kai Tak plot could fetch US$3.25 billion, smashing records for Hong Kong land sales

2018-05-11 scmp
Developers are forming consortiums to spread the financial risk of bidding for a residential site that could fetch an estimated US$3.25 billion
SHGKY KRYPY LFSYF 0083 1212 0683 0012 SUHJF SUHJY 0016 SHGKF M35 KRYPF LFSYY

0
Developers’ hoard of empty flats aggravates Hong Kong’s housing crisis. Will a tax fix it?

2018-04-15 scmp
Close to 300 flats lie disturbingly vacant in a completed new residential development in Ho Man Tin even as the Hong Kong government struggles to resolve the perennial short supply of housing in the world’s most expensive property market.
SUHJY 0017 0016 SHGKF SHGKY KRYPY KRYPF 0012 0683 SUHJF

Related Articles

REPH: Recro Pharma Analysis and Research Report

1h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

1h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...